anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bacterial infections are the primary cause of pathogenic sepsis. An uropathogenic E. coli (UPEC) model of monomicrobial sepsis represents a useful tool for interrogating the host immune response to this pathogen. Here, we present a protocol for inducing monomicrobial sepsis in mice using UPEC. We describe steps for preparing the bacteria, delivering UPEC into mice, and monitoring the mice post-infection. We then detail procedures for measuring cytokine response and detecting immune cell subsets using flow cytometry. For complete details on the use and execution of this protocol, please refer to Martin et al.1.
Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.
The invention relates to pharmaceutical composition for treating oral cavity diseases. The composition comprises a therapeutic agent in a biocompatible polymeric material. The therapeutic agent is soluble both in water and in alcohol and the biocompatible polymeric material is a liquid alcoholic methacrylate copolymer chosen among EUDRAGIT RL or EUDRAGIT RS or a mixture thereof. The biocompatible polymeric material and therapeutic agent are mixed in composition without release adjusting agents or plasticizer. And film is formed after evaporation of alcohol from alcoholic solution. At that, therapeutic agent releases gradual at water penetration through polymeric material of film. Moreover, invention relates to combination for bald dentine desensitization, where first composition comprises a therapeutic agent in a biocompatible polymeric material, at that the therapeutic agent is soluble both in water and in alcohol and represented as alcoholic solution or alcoholic gel of zinc salt and salt, picked from calcium salt or strontium salt, or a combination thereof. Biocompatible polymeric material is a liquid alcoholic methacrylate copolymer chosen among EUDRAGIT RL or EUDRAGIT RS or a mixture thereof. The biocompatible polymeric material and therapeutic agent are mixed in first composition without release adjusting agents or plasticizer and represents alcoholic solution or alcoholic gel. The second composition comprises a water solution or aqueous gel of potassium fluoride.
Orbital decompression was performed by the same doctor with rich clinical experience. MPT should be implemented in the patients with obvious thyroid disorder before orbital decompression surgery which should only be performed when thyroid function was stabilized. The surgery was performed under general anesthesia. An arcuate incision was made in the skin 2 mm below the lower eyelid margin, and the tissue under the incision were separated to the periorbita and orbital septum. Part of the medial orbital wall, inferior orbital wall and partial tissue of ethmoidal sinus were removed, and an appropriate amount of adipose tissue was excised. MPT was conducted after the surgery, at a dose of 1g methylprednisolone per day through intravenous injection for 3 consecutive days with a total amount of 3g methylprednisolone. After 3 days of intravenous injection of methylprednisolone, prednisone was orally taken by the patients at a dose of 30 mg/day which was gradually reduced.
FIELD: medicine, pharmacy. SUBSTANCE: mercuric chloride is dissolved in whey containing sucrose (27-33 g/l). Then the prepared solution is heated on water bath at 35-45 C for 15-20 min. Then mixture is kept at 5-10 C for 4-6 days. Preparation shows the expressed cytostatic effect on tumor cultures and immunotropic action and induces lymphocyte stimulation. Method can be used in pharmaceutical industry for making mercury-containing preparations showing antitumor activity. EFFECT: improved method of agent preparing. 1 tbl
Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
The present invention relates to newly identified polynucleotides, and polypeptides encoded by such polynucleotides, the use of such polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, a polypeptide of the present invention is a heparanase-related endoglucuronidase. The invention also relates to vectors and host cells comprising a polynucleotide of the invention. Furthermore, the invention relates to antibodies directed to polypeptides according to the present invention and to pharmaceutical compositions and diagnostic reagents comprising such antibodies, polypeptides or polynucleotides. The invention further relates to a method of altering, modifying or otherwise modulating the level of expression of the heparanase-related endoglucuronidase in a cell or in a organism. A further aspect of the invention are assay systems suitable for identifying modulators, e.g. agonists or antagonists of such polypeptides.
An understanding of the role of specific neurotransmitters in the neurocognitive functions mediating emotional processing is essential for the understanding and treatment of mood and anxiety disorders. One such disorder, currently regarded as untreatable, is psychopathy. Psychopathy has been linked with noradrenergic and amygdala disturbances. However, an understanding of the functional significance of the noradrenergic system in humans remains in its infancy. The goal of this protocol is to use targeted noradrenergic manipulations (yohimbine and guanfacine) in conjunction with specific neurocognitive and neuroimaging paradigms to consider the role of norepinephrine in reward and punishment processing. In particular, we wish to evaluate the hypothesis that increased norepinephrine levels following the administration of yohimbine will lead to enhanced formation and processing of stimulus-reward and stimulus-punishment associations, while decreased norepinephrine levels following the administration of guanfacine will reduce the formation and processing of stimulus-reward and stimulus-punishment associations. In addition, we aim to examine the hypothesis that increased norepinephrine levels will lead to increased neural response in the amygdala during either the formation, or processing, of stimulus-reinforcement associations.
PROBLEM TO BE SOLVED: To provide a new and safe Maillard reaction inhibitor, cosmetic composition or food/beverage. SOLUTION: This Maillard reaction inhibitor, cosmetic composition or food/ beverage includes at least one kind of extract from plant (s) selected from Akebia, Aloe, Prunusarmeniaca Linne var. anzu Maximowicz, Piper methysticum Forst., Platycodon, Kadsura, Panax sanchi Hoo, Bidens tripartita L., Polygonatum falcatum A. Gray, stellaria, Tetragonia, Ponia cocos(Fr.) Wolf and Citrus junos Tanaka. The above cosmetic composition or food/beverage can be utilized as the Maillard reaction inhibitor, affords the skin with firmness, is effective for preventing/ameliorating dry skin, can be utilized in preventing and treating diseases associated with various Maillard reaction inhibitions including skin resilience decline such as skin wrinkles and flabbiness, skin aging and diabetes-derived complications, and also is highly safe even if used internally or externally.
The invention relates to the preparing method and application of the total triterpene extracts from American solidago decurense. The total triterpene glycosides in the total triterpene extracts include Solidago decurense saponin 1,2,3 and 4, which can prevent and/or treat esophageal cancer, senile dementia, respiratory tract disease caused by different kinds of inflammation such as laryngopharyngitis and tracheitis. The diseases mentioned has been the main pathogeny that influences the quality of human life. The preparing technology of the extract is very simple, the extracting efficiency is very high; the extracts have strong pharmacologic action, stable quality and controllable quality; it's safe with less toxicity. The American Solidago decurense has damaged Chinese natural resources and ecological environment seriously as foreign invasive plant, it has been removed as weeds in many places. The invention can change waste into treasure while providing a new medicine source for preventing, diagnosing, detecting, protecting, treating and researching the mentioned diseases.
Despite the robust literature demonstrating improved outcomes with the use of mineralocorticoid antagonists (MRAs) in patients with heart failure with reduced ejection fraction (HFrEF), MRAs continue to be underused in clinical practice. This underuse often stems from the perceived risks of hyperkalemia, including a prior history of hyperkalemia and acute or chronic kidney disease, as well as the cautioned use for those with potassium greater than 5.0 mEq/L, as recommended in national societal guidelines. New potassium binders have recently been approved by the United States Food and Drug Administration (FDA) to treat hyperkalemia. It remains unknown if a best practice alert built into the clinical electronic health record can facilitate MRA prescription in eligible patients by providing guideline-based information about MRA recommendations and evidence, as well as informing practitioners about available treatments for hyperkalemia.

This is a pragmatic, cluster-randomized, open-label interventional trial to test the comparative effectiveness of an EHR BPA system that informs practitioners about MRAs for HFrEF and, if necessary, potassium-binders that are FDA-approved for hyperkalemia, versus usual care (no alert, current standard of care). One hundred and fifty outpatient Cardiology and Internal Medicine providers (to include physicians and advanced practice providers (nurse practitioners, physician assistants, and advanced practice registered nurses)) practicing at affiliated locations will be enrolled and undergo randomization to either the intervention (alert) group or a control (usual care) group. Those in the intervention group will receive an informational alert for their eligible adult outpatients (those with HFrEF not currently prescribed an MRA). Those in the control group will not receive any alerts and will continue to care for patients as usual. The primary outcome will be the proportion of patients with HFrEF who have an active prescription for an MRA at 6 months following randomization.
The control arm will receive the quality improvement intervention currently in place in the Québec Trauma Care Continuum (i.e. simple A\&F report presenting their performance compared to peers on quality indicators measuring adherence to high-value care and risk-adjusted outcomes) with the addition of quality indicators on low-value care (already planned by provincial authorities for the 2023 evaluation cycle). Simple A\&F was chosen for the control because it is standard practice in Québec and in most integrated trauma systems and the effectiveness of A\&F for de-implementation has been documented.
This open label pilot study will randomize 60 participants with GPA in remission affecting the sinonasal tract, oral mucosa, skin, musculoskeletal system, pulmonary parenchyma, or other disease features that warranted an administration of 20 mg/day or more within the last 12 months. At the time of enrollment, participants will need to be taking prednisone at a dose of ≥ 5mg/day and ≤ 20 mg/day. All enrolled participants will be instructed to reduce the daily dose of prednisone according to their treating physician. Once participants reach a prednisone dose of 5mg/day, they will be randomized at a 1:1 ratio to continue prednisone at 5 mg/day or to taper prednisone to 0 mg/day. Participants will be followed for approximately six months from reaching a prednisone dose of 5 mg/day.

The primary study outcome is the proportion of participants who increase prednisone for disease relapse within 6 months of randomization. Participant data collected via this study will be combined with that from a complementary study conducted at Vasculitis Clinical Research Consortium (VCRC) clinical centers.
To adequately prepare for potential hazards caused by emerging and reemerging infectious diseases, the WHO has issued a list of high-priority pathogens that are likely to cause future outbreaks and for which research and development (R&D) efforts are dedicated, known as paramount R&D blueprints. Within R&D efforts, the goal is to obtain effective prophylactic and therapeutic approaches, which depends on a comprehensive knowledge of the etiology, epidemiology, and pathogenesis of these diseases. In this process, the accessibility of animal models is a priority bottleneck because it plays a key role in bridging the gap between in-depth understanding and control efforts for infectious diseases. Here, we reviewed preclinical animal models for high priority disease in terms of their ability to simulate human infections, including both natural susceptibility models, artificially engineered models, and surrogate models. In addition, we have thoroughly reviewed the current landscape of vaccines, antibodies, and small molecule drugs, particularly hopeful candidates in the advanced stages of these infectious diseases. More importantly, focusing on global trends and novel technologies, several aspects of the prevention and control of infectious disease were discussed in detail, including but not limited to gaps in currently available animal models and medical responses, better immune correlates of protection established in animal models and humans, further understanding of disease mechanisms, and the role of artificial intelligence in guiding or supplementing the development of animal models, vaccines, and drugs. Overall, this review described pioneering approaches and sophisticated techniques involved in the study of the epidemiology, pathogenesis, prevention, and clinical theatment of WHO high-priority pathogens and proposed potential directions. Technological advances in these aspects would consolidate the line of defense, thus ensuring a timely response to WHO high priority pathogens.
The present invention discloses a pure Chinese preparation for treating femoral head necrosis and a preparing method of a pure Chinese preparation for treating femoral head necrosis. The formula of the pure Chinese preparation for treating femur head necrosis comprises the following ingredients: astragalus roots, fleece-flower roots, cibot rhizome, eucommia bark, Chinese angelica roots, Chinese wolfberries, hippocampi, aweto, pearls, turtle shells, tortoise plastrons, scorpios, scolopendras, long-noded pit vipers, antlers, etc. which are pure Chinese herbal medicines. The preparing method comprises the following procedures: the fifteen Chinese herbal medicines are selected, proportionally metered, placed in a marmite and dried for 20 mintues; the Chinese herbal medicines are mixed, sterilized and pulverized into 120 meshes of powder after the fleece-flower roots, the turtle shells and the tortoise plastrons are matured; pills are prepared by using honey, and the ratio of the honey and the Chinese herbal medicines is 1: 1; the Chinese herbal medicines are sterilized for the second time, sealed and packaged. The pure Chinese preparation for treating femur head necrosis has the advantages of nontoxicity and no side effect. The curative rate of the pure Chinese preparation for treating femoral head necrosis is 82.8%, and the effective rate is 96.2%.
An exfoliating cream and method of forming. The cream includes particles of a stone. The stone may be a precious or semi-precious stone of a characteristic color. The cream appears to be the color of the characteristic color. The cream may also include coloring agents to impart the characteristic color. The cream may also include particles of barium glass as another exfoliant. The cream may also include whole stone cells as another exfoliant.
There were no effects on fetal development or maternal toxicity when nelfinavir was administered to pregnant rats at systemic exposures (AUC) comparable to human exposure. Administration of nelfinavir to pregnant rabbits resulted in no fetal development effects up to a dose at which a slight decrease in maternal body weight was observed; however, even at the highest dose evaluated, systemic exposure in rabbits was significantly lower than human exposure. Additional studies in rats indicated that exposure to nelfinavir in females from mid-pregnancy through lactation had no effect on the survival, growth, and development of the offspring to weaning. Subsequent reproductive performance of these offspring was also not affected by maternal exposure to nelfinavir. However, there are no adequate and well-controlled studies in pregnant women taking VIRACEPT. Because animal reproduction studies are not always predictive of human response, VIRACEPT should be used during pregnancy only if clearly needed.
Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
Propranolol is not significantly dialyzable. In the event of overdosage or exaggerated response, the following measures should be employed:

General: If ingestion is or may have been recent, evacuate gastric contents, taking care to prevent pulmonary aspiration. 

Supportive Therapy: Hypotension and bradycardia have been reported following propranolol overdose and should be treated appropriately. Glucagon can exert potent inotropic and chronotropic effects and may be particularly useful for the treatment of hypotension or depressed myocardial function after a propranolol overdose. Glucagon should be administered as 50 to 150 mcg/kg intravenously followed by continuous drip of 1 to 5 mg/hour for positive chronotropic effect. Isoproterenol, dopamine or phosphodiesterase inhibitors may also be useful. Epinephrine, however, may provoke uncontrolled hypertension. Bradycardia can be treated with atropine or isoproterenol. Serious bradycardia may require temporary cardiac pacing. 

The electrocardiogram, pulse, blood pressure, neurobehavioral status and intake and output balance must be monitored. Isoproterenol and aminophylline may be used for bronchospasm.
Cerebral vein and dural venous sinus thromboses (CVST) account for 0.5%-1% of all strokes. Some structural factors associated with a potentially higher risk for developing CVST have been described. However, angulation of the dural venous sinuses (DVS) has yet to be studied as a structural factor. The current study was performed because this variable could be related to alterations in venous flow, thus predisposing to a greater risk of CVST development. Additionally, such information could help shed light on venous sinus stenosis (VSS) at or near the transverse-sigmoid junction. The angulations formed in the different segments of the grooves of the transverse (TS), sigmoid (SS), and superior sagittal sinuses (SSS) were measured in 52 skulls (104 sides). The overall angulation of the TS groove was measured using two reference points. Other variables were examined, such as the communication pattern at the sinuses' confluence and the sinus grooves' lengths and widths. The patterns of communication between sides were compared statistically. The most typical communication pattern at the sinuses' confluence was a right-dominant TS groove (82.98%). The mean angulations of the entire left TS groove at two different points (A and B) were 46° and 43°. Those of the right TS groove were 44° and 45°. The median angulations of the left and right SSS-transverse sinus junction grooves were 127° and 124°. The mean angulations of the left and right TS-SSJsv grooves were 111° (range 82°-152°) and 103° (range 79°-130°). Differentiating normal and abnormal angulations of the DVSs of the posterior cranial fossa can help to explain why some patients are more susceptible to pathologies affecting the DVSs, such as CVST and VSS. Future application of these findings to patients with such pathologies is now necessary to extrapolate our results.
Rare diseases pose significant challenges due to their heterogeneity and lack of knowledge. This study develops a comprehensive pipeline interoperable with a document-oriented clinical data warehouse, integrating cohort characterization, patient clustering and interpretation. Leveraging NLP, semantic similarity, machine learning and visualization, the pipeline enables the identification of prevalent phenotype patterns and patient stratification. To enhance interpretability, discriminant phenotypes characterizing each cluster are provided. Users can visually test hypotheses by marking patients exhibiting specific keywords in the EHR like genes, drugs and procedures. Implemented through a web interface, the pipeline enables clinicians to navigate through different modules, discover intricate patterns and generate interpretable insights that may advance rare diseases understanding, guide decision-making, and ultimately improve patient outcomes.
The cytoskeleton facilitates tumor cells invasion into the bloodstream via vasculogenic mimicry (VM) for "attack", and protects cells against external threats through cytoskeletal remodeling and tunneling nanotubes (TNTs) for "defense". However, the existing strategies involving cytoskeleton are not sufficient to eliminate tumor metastasis due to mitochondrial energy supply, both within tumor cells and from outside microenvironment. Here, considering the close relationship between cytoskeleton and mitochondria both in location and function, we construct a nano-platform that combats the "attack" and "defense" of cytoskeleton in the cascading metastasis. The nano-platform is composed of KFCsk@LIP and KTMito@LIP for the cytoskeletal collapse and mitochondrial dysfunction. KFCsk@LIP prevents the initiation and circulation of cascading tumor metastasis, but arouses limited suppression in tumor cell proliferation. KTMito@LIP impairs mitochondria to trigger apoptosis and impede energy supply both from inside and outside, leading to an amplified effect for metastasis suppression. Further mechanisms studies reveal that the formation of VM and TNTs are seriously obstructed. Both in situ and circulating tumor cells are disabled. Subsequently, the broken metastasis cascade results in a remarkable anti-metastasis effect. Collectively, based on the nano-platform, the cytoskeletal collapse with synchronous mitochondrial dysfunction provides a potential therapeutic strategy for cascading tumor metastasis suppression.